Latest Breaking News On - Prnewswire leap therapeutics inc - Page 1 : comparemela.com

Leap Therapeutics Reports First Quarter 2024 Financial Results

Leap Therapeutics Reports First Quarter 2024 Financial Results
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesMatthew deyoungDouglase onsiPrnewswire leap therapeutics incAmerican society of clinical oncologyGilead sciences incDrug administrationLeap therapeutics incGilead sciencesSamsara biocapitalLaurion capital managementRock springsChief executive officerCommon stockDefiance study

Leap Therapeutics Announces $40 Million Private Placement

Leap Therapeutics Announces $40 Million Private Placement
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesMatthew deyoungDouglase onsiDrug administrationPrnewswire leap therapeutics incLeap therapeutics incExchange commissionGilead sciences incCompany common stockCommon stockGilead sciencesSamsara biocapitalLaurion capital managementRock springsDefiance study

Leap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal Cancers Symposium

Leap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal Cancers Symposium
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomSan franciscoMatthew deyoungMeredith pelsterDouglase onsiZev wainbergDrug administrationLeap therapeutics incAmerican society of clinical oncologyGi oncology programPrnewswire leap therapeutics incGastrointestinal research at sarah cannon institutePresent new clinical dataDefiance studyClinical oncology

Leap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal Cancers Symposium

/PRNewswire/ Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced.

San franciscoUnited statesUnited kingdomZev wainbergDouglase onsiMatthew deyoungMeredith pelsterDrug administrationPrnewswire leap therapeutics incAmerican society of clinical oncologyGi oncology programGastrointestinal research at sarah cannon instituteLeap therapeutics incClinical oncologyGastrointestinal cancers symposiumAssistant director

Leap Therapeutics to Present New Data from Part A of the DeFianCe Study of DKN-01 Plus Bevacizumab and Chemotherapy in Colorectal Cancer Patients at the 2024 ASCO Gastrointestinal Cancers Symposium

Leap Therapeutics to Present New Data from Part A of the DeFianCe Study of DKN-01 Plus Bevacizumab and Chemotherapy in Colorectal Cancer Patients at the 2024 ASCO Gastrointestinal Cancers Symposium
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomSan franciscoDouglase onsiMatthew deyoungMeredith pelsterMsc sarah cannon research instituteAmerican society of clinical oncologyPrnewswire leap therapeutics incDrug administrationLeap therapeutics incClinical oncologyGastrointestinal cancersPresentation detailsSarah cannon research institutePoster discussion